Mirati Therapeutics, Inc. (MRTX) News

Mirati Therapeutics, Inc. (MRTX): $68.16

2.27 (+3.45%)

POWR Rating

Component Grades













Add MRTX to Watchlist
Sign Up

Industry: Biotech


of 396

in industry

Filter MRTX News Items

MRTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MRTX News Highlights

  • MRTX's 30 day story count now stands at 33.
  • Over the past 27 days, the trend for MRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
  • The most mentioned tickers in articles about MRTX are DRUG, LUNG and USER.

Latest MRTX News From Around the Web

Below are the latest news stories about Mirati Therapeutics Inc that investors may wish to consider to help them evaluate MRTX as an investment opportunity.

Is a Surprise Coming for Mirati (MRTX) This Earnings Season?

Mirati (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | February 25, 2022

5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Yahoo | February 24, 2022

Mirati (MRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 21, 2022

Mirati (MRTX) Down on Longer Review Period for Adagrasib NDA

The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.

Yahoo | February 17, 2022

JonesTrading Thinks Mirati Therapeutics’ Stock is Going to Recover

JonesTrading analyst Soumit Roy reiterated a Buy rating on Mirati Therapeutics (MRTX – Research Report) today and set a price target of $165.00. The company's shares closed last Tuesday at $107.39, close to its 52-week low of $98.55. According to TipRanks.com, Roy is a 4-star analyst with an average return of 12.9% and a 32.9% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Monopar Therapeutics Inc, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mirati Therapeutics with a $168.20 average price target, implying a 63.4% upside from current levels.

Catie Powers on TipRanks | February 16, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We've got another busy day of trading ahead of us so let's get right to it with the biggest pre-market stock movers for Wednesday!

William White on InvestorPlace | February 16, 2022

Why Mirati Therapeutics Stock Is Plunging Today

A longer-than-expected regulatory review for the company''s lung cancer drug is weighing on its shares today.

The Motley Fool | February 16, 2022

Biotech Stock Values Cut in Half While New Drug Setbacks Pile Up - BNN Bloomberg

(Bloomberg) -- Former high flying biotechnology favorites Mirati Therapeutics Inc. and Sage Therapeutics Inc. have lost more than half their value from record highs, hurt by growing pessimism on new medicines as well as the higher rate environment damaging most stocks.

BNN Bloomberg | February 16, 2022

Mirati stock falls as KRAS inhibitor goes under FDA review for lung cancer (MRTX)

Mirati Therapeutics (MRTX) is trading ~7% lower in the pre-market on Wednesday. Read more about the reason

Seeking Alpha | February 16, 2022

Mirati price targets cut at Street firms following longer adagrasib review timeline

At least two Street firms have cut price targets on Mirati Therapeutics (MRTX) after the company Tuesday said its New Drug Application for its KRAS inhibitor. adagrasib will get a…

Seeking Alpha | February 16, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5453 seconds.